medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2013, Number 1

<< Back

Residente 2013; 8 (1)

Síndrome de lisis tumoral

González-Sánchez AG, Rubio-Jurado B, Guerra-Soto AJ, Verdugo-Meza RA, Nava A

Language: Spanish
References: 10
Page: 35-43
PDF size: 122.50 Kb.


ABSTRACT

Tumor lysis syndrome is a major metabolic disorder which is frequently found after cell destruction produced in most cases subsequent to the initiation of cytotoxic therapy, used in a variety of cancers including lymphoma, leukemia and neuroblastoma. The rapid cellular destruction causes the abrupt release of intracellular ions, nucleic acids, proteins and metabolites into the extracellular space. These metabolites can overcome the homeostatic mechanisms causing hypocalcemia, hyperkalemia, hyperphosphatemia and uremia. Tumor lysis syndrome can lead to acute renal failure and can be life threatening patient. Early recognition of patients at risk and the initiation of new therapeutic approaches for tumor lysis syndrome is essential.


REFERENCES

  1. Scott CH, Jones DP, Ching-Hon P. The tumor lisys syndrome. N Engl J Med. 2011: 364: 1844-1854.

  2. Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber MJ Jr. Tumor lysis syndrome. Semin Thromb Hemost. 2007; 33: 397-407.

  3. Ararambide K, Toto RD. Tumor lysis syndrome. Semin Nephrol. 1993; 13: 273-280.

  4. Cairo MS, Coiffi er B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumor lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus. Br J Hematol. 2010; 149: 578-586.

  5. Salit RB, Bishop MR. The envolving world of tumor lysis syndrome. How we treat tumor lysis syndrome. Oncology. 2011; 369-337.

  6. Coiffi er B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the managementof pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008; 26: 2767-2778. [Erratum, J ClinOncol 2010;28:708.]

  7. Cairo MS, Bishop M. Tumor Lysis Syndrome: new therapeutic strategies and classifi cation. Br J Haematol. 2004; 127: 3-11.

  8. Graciela E, Rossi N, Parias N, Donato H. Guidelines for management of tumor lysis syndrome. Arch Argent Pediatr. 2011; 109: 77-82.

  9. Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA et al. Rasburicase (Recombinant Urate Oxidase) for the management of hyperuricemia in patients with cancer, Am Cancer Soc. 2003; 98 (5): 1048-1054.

  10. Solh M, Appel J. Tumor lysis syndrome, Hospital physician. Resident Grand Rounds 2008, 25-29.




2020     |     www.medigraphic.com